CollPlant Biotechnologies
CLGN
16 hedge funds and large institutions have $19.5M invested in CollPlant Biotechnologies in 2022 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 7 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.12% less ownership
Funds ownership: 1.69% → 1.56% (-0.12%)
24% less funds holding
Funds holding: 21 → 16 (-5)
34% less capital invested
Capital invested by funds: $29.5M → $19.5M (-$10M)
71% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RAM
Roumell Asset Management
Chevy Chase,
Maryland
|
+$1.12M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$695K |
| 3 |
BFEC
Benjamin F. Edwards & Company
St. Louis,
Missouri
|
+$182K |
| 4 |
Brown Advisory
Baltimore,
Maryland
|
+$176K |
| 5 |
SDJVC
St. Denis J. Villere & Co
New Orleans,
Louisiana
|
+$100K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IMOV
Investment Management of Virginia
Richmond,
Virginia
|
-$1.88M |
| 2 |
Zurich Cantonal Bank
Zurich,
Switzerland
|
-$403K |
| 3 |
WC
Weil Company
San Diego,
California
|
-$347K |
| 4 |
KWM
Kingsview Wealth Management
Grants Pass,
Oregon
|
-$301K |
| 5 |
LPL Financial
San Diego,
California
|
-$242K |
CLGN Hedge Fund Activity: Q1 2022 in Review
16 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in CollPlant Biotechnologies (CLGN) for Q1 2022, worth a combined $19.5M — down 34% from $29.5M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of CLGN and 2 opened new positions — a net loss of 5 holders — while 5 trimmed existing stakes and 6 added.
The largest buyer was Roumell Asset Management, adding an estimated $1.12M. The largest seller was Investment Management of Virginia, cutting an estimated $1.88M.
- 16 institutional investors held CollPlant Biotechnologies (CLGN) as of Q1 2022, down from 21 in Q4 2021.
- Funds reported $19.5M of CollPlant Biotechnologies stock for Q1 2022, down 34% quarter-over-quarter.
- 2 funds opened new CollPlant Biotechnologies positions in Q1 2022 and 7 closed out, a net change of -5 holders.
- The largest CollPlant Biotechnologies buyer in Q1 2022 was Roumell Asset Management, an estimated $1.12M added.
- The largest CollPlant Biotechnologies seller in Q1 2022 was Investment Management of Virginia, an estimated $1.88M sold.
Based on aggregated 13F filings for Q1 2022.